A trial of talimogene laherparepvec and pembrolizumab for head and neck cancers

Please note

This trial is no longer recruiting patients. We hope to add results when they are available.

Overview

Cancer types:

Head and neck cancers, Laryngeal cancer, Mouth and oropharyngeal cancer, Nasal and paranasal sinus cancer , Salivary gland cancer

Status:

Closed

Phase:

Phase 1

Details

This trial is for people with a head and neck cancer that has come back after treatment (recurred) or has spread to another part of the body (metastatic).

Talimogene laherparepvec is a form of the cold sore virus. It has been changed so it isn’t harmful to normal cells, but destroys cancer cells. The virus is changed by altering the genes that tell it how to behave.

Recruitment start: 22 May 2017

Recruitment end: 22 August 2017